Ocular Therapeutix Posts $94.8M Third-Quarter Loss
OCUL is trading near its 52-week low of $6 (9.8% above the low).
Summary
Ocular Therapeutix reported a $94.8 million net loss for the third quarter. That is a steep figure for a company of this size and continues the pattern of rising losses and cash burn flagged in the last 10-Q, which showed a larger Q2 loss alongside a plan to file the AXPAXLI NDA in wet AMD in Q4 2026. The loss likely reflects heavy spending on the AXPAXLI program ahead of that submission rather than an operational surprise, but the headline number alone gives no revenue, per-share or cash balance detail. The key question is whether the company reaffirmed its cash runway into 2028 and the Q4 2026 NDA timeline. Watch the AXPAXLI NDA submission, expected in Q4 2026.
At the time of this announcement, OCUL was trading at $6.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $6.00 to $16.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.